Literature DB >> 22678941

'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome.

Henrietta Bowden Jones1, Sanju George.   

Abstract

Dopaminergic agents are commonly used and effective treatments for restless legs syndrome (RLS), a disabling sensorimotor disorder. Less known are some of the potentially disabling side effects of these treatments, particularly iatrogenic gambling addiction, as is described here. Here the authors present a 62-year-old man, with a 20-year history of RLS, who developed gambling addiction while on dopaminergic treatment. He was not forewarned of this side effect, nor was he ever screened for gambling behaviours prior to or during treatment. Eight months after discontinuation of dopaminergic treatment and after 10 sessions of cognitive-behavioural therapy for gambling addiction, his gambling behaviours have partially resolved. To our knowledge, this is the first ever first person account of this condition. To prevent the devastating consequences of gambling addiction or to minimise its impact by early intervention, the authors call for clinicians involved in treatment of RLS to follow these simple measures: screen patients for gambling behaviours prior to the onset and during dopaminergic treatment; forewarn patients of this potential side effect; and if patients screen positive, refer them to specialist gambling treatment services, in addition to making necessary changes to their medication regime.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22678941      PMCID: PMC3171036          DOI: 10.1136/bcr.07.2011.4459

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists.

Authors:  M Tippmann-Peikert; J G Park; B F Boeve; J W Shepard; M H Silber
Journal:  Neurology       Date:  2007-01-23       Impact factor: 9.910

2.  Pathological gambling associated with dopamine agonist use in restless legs syndrome.

Authors:  Jeremy Quickfall; Oksana Suchowersky
Journal:  Parkinsonism Relat Disord       Date:  2007-01-30       Impact factor: 4.891

Review 3.  The prevalence and clinical characteristics of pathological gambling in Parkinson's disease: an evidence-based review.

Authors:  M P Barns Neurauter; Hugh Rickards; Andrea Eugenio Cavanna
Journal:  Funct Neurol       Date:  2010 Jan-Mar

4.  Pathological gambling plus hypersexuality in restless legs syndrome: a new case.

Authors:  Giuseppe d'Orsi; Vincenzo Demaio; L M Specchio
Journal:  Neurol Sci       Date:  2011-05-13       Impact factor: 3.307

5.  Restless legs syndrome: a community-based study of prevalence, severity, and risk factors.

Authors:  B Högl; S Kiechl; J Willeit; M Saletu; B Frauscher; K Seppi; J Müller; G Rungger; A Gasperi; G Wenning; W Poewe
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

6.  The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

Authors:  Dien Dang; David Cunnington; John Swieca
Journal:  Clin Neuropharmacol       Date:  2011 Mar-Apr       Impact factor: 1.592

Review 7.  Restless legs syndrome: a clinical update.

Authors:  Charlene E Gamaldo; Christopher J Earley
Journal:  Chest       Date:  2006-11       Impact factor: 9.410

Review 8.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

Authors:  Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

9.  Compulsive habits in restless legs syndrome patients under dopaminergic treatment.

Authors:  Emmanuelle Pourcher; Sophie Rémillard; Henri Cohen
Journal:  J Neurol Sci       Date:  2009-12-06       Impact factor: 3.181

10.  Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.

Authors:  Erika D Driver-Dunckley; Brie N Noble; Joseph G Hentz; Virgilio G H Evidente; John N Caviness; James Parish; Lois Krahn; Charles H Adler
Journal:  Clin Neuropharmacol       Date:  2007 Sep-Oct       Impact factor: 1.592

View more
  3 in total

1.  Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.

Authors:  Cheryl Hankin; Daniel Lee; Diego Garcia-Borreguero; Zhaohui Wang
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

Review 2.  Restless legs syndrome: Over 50 years of European contribution.

Authors:  Samson G Khachatryan; Raffaele Ferri; Stephany Fulda; Diego Garcia-Borreguero; Mauro Manconi; Maria-Lucia Muntean; Ambra Stefani
Journal:  J Sleep Res       Date:  2022-07-09       Impact factor: 5.296

Review 3.  Dopamine Agonists and Impulse Control Disorders: A Complex Association.

Authors:  Marie Grall-Bronnec; Caroline Victorri-Vigneau; Yann Donnio; Juliette Leboucher; Morgane Rousselet; Elsa Thiabaud; Nicolas Zreika; Pascal Derkinderen; Gaëlle Challet-Bouju
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.